{"id":"W2755049090","doi":"10.1136/annrheumdis-2017-eular.2443","title":"OP0202 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"AbbVie; Celgene; Chugai Pharmaceutical; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Tofacitinib; Psoriatic arthritis; Janus kinase inhibitor; Discontinuation; Internal medicine; Psoriasis Area and Severity Index; Psoriasis; Adverse effect; Placebo; Clinical endpoint; Rheumatoid arthritis; Gastroenterology; Surgery; Randomized controlled trial; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001040076,0.0003609129,0.001479345,0.000312273,0.0003284297,0.0001436531,0.0003411897,0.0001033749,0.00005381682],"category_scores_gemma":[0.003445409,0.0002432276,0.0001847937,0.0001818461,0.0004959184,0.0007685221,0.0002185105,0.0002210671,0.000001917944],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002876389,"about_ca_system_score_gemma":0.0004340524,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003533757,"about_ca_topic_score_gemma":0.00007496633,"domain_scores_codex":[0.9965938,0.0007015357,0.001096436,0.0004343808,0.0007415588,0.0004323263],"domain_scores_gemma":[0.9970357,0.0005280313,0.000756821,0.0008633622,0.0003241152,0.0004919893],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8315339,0.002728813,0.002306914,0.000180482,0.0002384873,0.00001029326,0.001807549,0.00001053254,0.0001808674,0.000009978595,0.00003511225,0.160957],"study_design_scores_gemma":[0.8577595,0.007068194,0.1296255,0.001872107,0.0001815027,0.000001752266,0.0006354197,0.0001369475,0.002342772,0.00008695688,0.00002291642,0.0002665088],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912564,0.0003531884,0.000002985201,0.000734865,0.00008724139,0.007089946,0.0004250536,0.00001637127,0.00003390952],"genre_scores_gemma":[0.9992298,0.0001972444,0.00002895362,0.0000658362,0.00003531681,0.000313358,0.00005434841,0.00003735185,0.00003776882],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1606905,"threshold_uncertainty_score":0.9918534,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04150119976932149,"score_gpt":0.3519479655918908,"score_spread":0.3104467658225693,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}